30Jun
Healthcare M&A prospers, despite fall in deal activity
The megadeals of 2019 may be off the table for now, but deal activity across healthcare and pharmaceuticals has proven resilient through the COVID-19 crisis - Although pharma, medical and biotech (PMB) M&A deal value for Q1 2020 came in at US$39.3 billion, 78% below the year before, this was primarily due to the outsized US$87.8 billion deal between Bristol-Myers Squibb and Celgene in early 2019....
By:
White & Case LLP
Related
Wall Street apparently got together and decided that Monday was the day to start paying attention to...
Read More >
In the midst of a global Pandemic that is devastating to the health of our community and to our econ...
Read More >
On Tuesday, September 24, 2019, the United States Department of Labor (“Department”) announced its...
Read More >
Seyfarth Synposis: As of March 16, 2020, Colorado’s daily overtime and meal and rest break requirem...
Read More >
On December 17, 2019, the National Labor Relations Board (“Board”) ruled that an employer’s rule ...
Read More >
The Department of Justice Antitrust Division (the “Division”) recently released updated guidance o...
Read More >